and all other gastroenterologists and staff at every hospital who have assisted in identification and recruitment of patients. 
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[IBDU]; median age, 37 years) from 2011 through 2013. We analyzed disease course and severity and mortality. Risks for medical and surgical therapies were assessed using KaplanMeier analysis. Results: The cumulative probability that CD would change from inflammatory to stricturing or penetrating disease was 19.6%. The cumulative probabilities for use of immunosuppressants or anti-tumor necrosis factor (TNF) agents were 58.9% and 12.0% for patients with CD, and 12.7% and 0.9% for patients with UC, respectively. Perianal CD was associated with an increased risk of anti-TNF therapy within 1 year of its diagnosis (HR, 2.97; 95% CI, 1.09-8.09). The cumulative probabilities for surgery 1 year after diagnosis were 9.1% for patients with CD and 0.9% for patients with UC. Patients with CD and penetrating disease had a 7-fold increase for risk of surgery, compared to patients with inflammatory disease (HR, 7.67; 95% CI, 3.93-14.96). Overall mortality for patients with IBD was 0.7%. Conclusion: In a prospective population-based study, we found that the early course of disease in patients with 
Background
Inflammatory bowel disease (IBD) incidence is increasing in Asia [1] [2] [3] . However, our current knowledge of the natural history of IBD in Asia remains limited because data are scarce at a population level and are mainly derived from referral centres and / or small-size series 1 . Such data are biased toward more severe disease.
Natural history studies provide invaluable data on chronic disabling diseases. They help to identify subsets of patients in whom disease prognosis can be stratified according to clinical features. These data may improve the management of patients with IBD by defining changes in disease phenotype over time, risk of relapse and hospitalizations, and risk of surgery. Such data may help develop therapeutic strategies aimed at modifying the clinical course of IBD in differing populations, and help to address both the health needs of patients and the social burden of these chronic diseases 4 . At present, most available population-based studies on disease outcome have been conducted before the era of disease-modifying agents and / or in Western countries 5 .
The Asia-Pacific Crohn's and Colitis Epidemiology Study (ACCESS) was initiated in 2011 to capture prospective incident IBD cases from nine countries in Asia-Pacific. Patients were recruited from well-defined geographical regions. We reported that the incidences of IBD varied within Asia and were lower than the West 3 . However, complicated Crohn's disease (stricturing, penetrating, or perianal disease) was identified in more than half of the patients at diagnosis. In the present study, we report results of early clinical outcome in 413 incident IBD patients, in M A N U S C R I P T
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7 particular, we have assessed disease course, disease severity, risk factors for medical therapy and surgery, as well as cancer mortality rates.
Methods
Cases were incident IBD subjects diagnosed between April 2011 and March 2013 living in predefined, well-described geographical areas from eight regions/countries in Asia (China, Hong
Kong, Indonesia, Sri Lanka, Macau, Malaysia, Singapore, Thailand) and Australia. The methodology for case ascertainment and capture has been described in detail previously 3 . Briefly, diagnostic criteria, time period of inclusion, patient clinical demographics and ascertainment methods were standardized. Only patients who had been resident in the defined study area at the time of diagnosis and had at least six months of follow-up data were included. Subjects with a initial diagnosis of IBD-undetermined (IBD-U) and who were subsequently diagnosed with
Crohn's disease (CD) or ulcerative colitis (UC) were included whereas those who remained as IBD-U at the end of follow-up were excluded.
Disease extent for UC and disease location and behavior for CD were defined according to the Montreal classification 6 . For CD, disease location included ileal (L1), colonic (L2), ileocolonic (L3) and upper gastrointestinal diseases (L4); disease behaviour included inflammatory (B1), stricturing (B2) and penetrating disease (B3); perianal lesions included perianal abscesses and / or fistulae. B2 (stricturing) and B3 (penetrating) were pooled and defined as 'complicated behaviour'. For UC, proctitis (E1) was defined as inflammation distal to the rectosigmoid junction, E2 as inflammation distal to the splenic flexure and E3 as inflammation proximal to the splenic flexure. 
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Data collection
Patients were followed-up prospectively every three months from diagnosis and throughout the follow-up period. A follow-up period of at least six months was selected to assess the early outcome of this cohort. Data on clinical demographics, disease phenotype, disease activity, medical or surgical therapy, hospitalization, cancer and mortality were obtained and
prospectively entered in the ACCESS database (http://www.access-apibd.com/access/index.html) at each visit. We compared disease characteristics and outcomes in Asia and Australia, and determined the risk of disease behavior change and probability of surgery.
Statistical analysis
Statistical analyses were performed using SPSS statistical software package (SPSS Inc, Chicago, IL, USA). Demographics and disease classification between the groups were compared using chi-square test. Subjects who were initially diagnosed as IBD-U and subsequently confirmed to have either CD or UC were included in the analysis according to their final diagnosis.
Cumulative probabilities and the 95% confidence intervals (CI) of each treatment and surgery were calculated using the Kaplan-Meier method. Risk factors for surgery, immunosuppressants and biologic use were measured using bivariate marginal cox proportional hazard models for clustered data. In this model, age, gender, smoking status, type of disease (CD or UC), disease behaviour and extent were included and factors with a p value less than 0.05 in univariate analysis were included in multivariate marginal cox proportional hazard regression to obtain the adjusted model and their corresponding hazard ratio and 95% confidence interval (CI).
Assumption was tested using a Kolmogorov-type supremum test and no significant violation was detected. Continuous variables were expressed as median and interquartile range. Statistical significance was considered p≤0.05.
Results
Patient characteristics
M A N U S C R I P T A C C E P T E D Disease extension occurred during follow-up in 11.5% of UC patients. Cumulative probability of disease extension for UC at maximal follow-up was 15.3% (95% CI, 9.5%-21.2%) in Asia and 4.2% (95% CI, 0%-12.2%) in Australia (Figure 1b ). Table 1 ).
Change in disease activity during the first year
Drug therapy
In Asia, 12.3% of patients with CD received steroids as initial therapy which reduced to 5.8% at one year follow-up (p=0.059). The frequency of use of immunosuppressants and anti-TNF agents increased from 19.6% and 4.3% at diagnosis to 47.1% and 11.6%, respectively, at one year (p<0.001 and p=0.026). Twenty two percent and 18.8% of patients with CD were on 5-ASA at diagnosis and at one year follow-up, respectively. For UC, steroids were used in 15.6% at diagnosis and 18.8% at one year. The frequency of immunosuppressant use increased from 4.2%
at diagnosis to 12.0% at one year whereas an anti-TNF agent was used in one patient at diagnosis M A N U S C R I P T
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and one year follow-up. Table 2 shows the medical therapy for IBD at baseline and at one year follow-up.
In Asia, the cumulative probability of receiving 5-ASA, corticosteroids, immunosuppressants and anti-TNF agent for CD was 60%, 44%, 63% and 12%, respectively. The cumulative probability of receiving 5-ASA, corticosteroids, immunosuppressants and anti-TNF agent for UC was 88%, 25%, 13% and 1%, respectively (Figures 2a and b) .
At one year after diagnosis, overall total steroid exposure for IBD was higher in Australia than in Cumulative probability of the use of immunosuppressants (63% vs 13%; p<0.001) and anti-TNF agent (12% vs 1%; p<0.001) during the first year of disease was higher in CD than UC in Asia.
Cumulative probability of immunosuppressant for UC in Asia was highest in patients with extensive/total colitis compared with distal colitis/proctitis (22.5% vs 10.3%; p=0.063). In patients with CD, cumulative probability of immunosuppressant use was higher in those with stricturing disease (73.1%) and penetrating disease (66.7%) than inflammatory disease (Figures   3a and b) . Table 2b ).
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Surgery
Twenty-three patients (12.3%) with CD underwent intestinal resective surgery up to maximal follow-up. Of those who had surgery, 17 (73.9%) had surgery within the first year of diagnosis.
Amongst these patients, 56.3% and 57.1% from Asia and Australia, respectively, had their surgery during the first three months after diagnosis. The median time from diagnosis to the first resection for all CD was two months (IQR, 0-15 months). Overall 11.6% of CD patients in Asia and 14.3% in Australia underwent surgical resection. The most frequent surgery was ileocecal resection (n=13) followed by small bowel resection (n=5) and total colectomy and ileostomy (n=5). The median time from diagnosis to surgery for Asia and Australia was not significantly different (2.5 months vs 2 months; p=1.000). At one year, the cumulative probability of surgical resection for CD was 8.0% in Asia and 12.2% in Australia (p = 0.775).
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Five patients with UC (2.2%) underwent a colectomy at maximal follow-up (3 from Asia; 2 from Australia). Overall 1.6% of UC patients in Asia and 5.9% in Australia underwent a colectomy (p=0.114). The median time from diagnosis to colectomy for UC was 15 months (IQR, 4.5-17.5 months). Amongst these patients, two patients from Asia and none from Australia had their colectomy within the first year of diagnosis. At one year, the cumulative probability of colectomy for UC was 1.1% in Asia and 0% in Australia (p = 0.548) at one year.
Factors associated with risk of surgery
In CD, patients with stricturing and penetrating disease had a higher likelihood of surgery than those with inflammatory disease (Figure 4) Table 3 ).
When these outcomes were adjusted based on region (Asia versus Australia), we found that the results remained unchanged (Supplementary Table 4) . Proportional hazard assumption was tested and no significant violation was detected.
Cancer and Mortality
During follow-up, six patients (1.5%) were diagnosed with cancers at a median of 10 months (range, 4-13 months) after diagnosis. These cancers included renal cancer, cholangiocarcinoma, hepatocellular carcinoma, lung carcinoma, oesophageal carcinoma and colorectal carcinoma.
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One UC patient aged 28 with concurrent primary sclerosing cholangitis was diagnosed with cholangiocarcinoma 10 months after diagnosis.
Three patients (0.7%) died during follow-up at a median of 4 months (range, 3-5) after diagnosis.
One CD patient died from uncontrolled sepsis, another CD patient died of oesophageal carcinoma and one UC patient died of lung cancer,
Discussion
This population-based study, to our knowledge, is the first and largest to report evolution of CD and UC in an inception cohort across Asia-Pacific. Our data reflected early disease outcomes in a large cohort of IBD patients across nine countries in Asia-Pacific followed over a median of 18 months. Major findings of this study were that early disease severity, evolution and clinical outcomes of IBD in Asia are largely similar to that of the West suggesting that healthcare practices and associated costs seen in the West is likely to apply to Asia. Almost one third of CD patients had stricturing or penetrating complications at diagnosis, and about one quarter developed intestinal complications at one year. Early surgical intervention rate for CD was high and a large number of CD patients still underwent intestinal resective surgery despite increasing use of immunosuppressants. Amongst patients with CD who had surgery, three quarters had surgery within the first year of diagnosis. Overall the natural history of Asian CD showed that the majority of patients have progression from inflammatory disease to development of complications 9 .
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To date, only few population-based studies have described the progression of CD behavior in and most of these studies were conducted in Western populations. The proportion of patients reported to have stricturing or penetrating complication at diagnosis ranged from 19% to 38% [10] [11] [12] [13] [14] . Our complication rate of 27% at presentation is unlikely to be related to delayed presentation or late diagnosis as median time from symptom onset to diagnosis was relatively short.
Cumulative probability of behavior change to complicated CD was 20% at one year and this corresponds to population-based data from Olmsted county whereby 22% of patients developed a stricturing or penetrating intestinal complication within one year of diagnosis 10 .
The risk of surgery associated with complicated disease behavior is well-established suggesting that once an intestinal complication has occurred drug therapy may have a limited role in prevention of surgery 11, 15 . As such, stricturing and penetrating diseases were associated with highest risk for surgery in CD 13 , suggesting that a proportion of patients with CD already have complications at diagnosis and surgery is likely to be unavoidable even with early use of biologics. Early disease course may represent a distinct entity not influenced by aggressive drug therapy. In a meta-analysis assessing risk of surgery for IBD in population-based settings, patients diagnosed after year 2000 had a 12.6% and 2.7% risk of surgery at one-year following the diagnosis for CD and UC, respectively 16 .
Clinical phenotypes of Asian IBD resemble those of the Caucasian population in general, but with some heterogeneity 17 , including a male predominance for CD and a lower family history of IBD 1, 18 . Almost half of the patients with CD had ileocolonic disease, which contrasts with data from Scandinavia where colonic CD (41%) was the most common 19 . This may in part be M A N U S C R I P T
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17 explained by genetic variations or recent advances in technology with better access to small bowel imaging or improved interpretation of bowel examination modalities in Asia.
Regarding drug therapy, corticosteroids were used in 44% with CD and in 25% with UC. The rates were higher in Australia than Asia. Frequency of use of corticosteroids in CD was previously reported to be 56-76% 20, 21 . The use of corticosteroids was relatively low in our study but the exact cause for this was not clear. In the European Crohn's and Colitis
Organization-EpiCom inception cohort, 55% of incident patients with CD in Western Europe
were treated with corticosteroids within first 3 months of diagnosis 13 . Population-based studies have reported the increasing use of thiopurines over the years from 11% in 1977 to 48% in 2008 [22] [23] [24] . The overall use of AZA was 22% during the 5-year follow-up of the IBSEN study 25 . In a Danish nationwide cohort study of over 40,000 IBD patients over a 32-year period, only patients with CD using azathioprine within the first 3 months after diagnosis had a reduced risk of reduced from 17% to 2% and those with moderate to severe UC from 67% to 36% over one year.
Twelve percent of patients with CD needed a resection within the first year after diagnosis, which concur with population based studies in the West reporting one year surgical rate for CD to range from 8% to 14% [27] [28] [29] [30] . In Denmark, intestinal resection rates among patients with CD in the year of diagnosis ranged from 12% to 35% 19 . Cumulative colectomy rates from studies in the West at one year was 6-11%, at 5 years was 20% and at 10 years was 24-28% 20, 31 . Patients with stricturing and penetrating diseases have a higher likelihood of surgery. We found no difference in surgical rate for patients with complex CD in Asia and Australia. A populationbased study from Olmsted County reported that 20% of patients required surgery within 3 months of diagnosis and cumulative risk for first intestinal resection was 24%, 49%, and 64% at years 1, 10, and 30, respectively 32 . Our cumulative surgical resection rate for CD of 8.0% at one year is similar to those of Europe, but lower than that of Olmsted country data. In general, surgery rates appear to have declined in the past two decades based on surgical patterns and rates from population-based studies 33 . It remains unclear if this is the result of increasing and earlier use of immunosuppressants during this period.
In Asia colectomy rates for UC at one year are lower (2.0 to 4.1%) 34, 35 36 . In this study the cumulative colectomy rate for UC was 1.1%. It is unclear whether this lower colectomy rate related to milder disease presentation and course in Asian subjects, variations in management in Asia, or different physician and patient thresholds for colectomy. Whether there is a less aggressive UC natural history amongst Asians remains to be confirmed.
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The major strength of this study is the population-based design across a large but well-defined geographic area in Asia-Pacific. Strict and uniform diagnostic criteria were applied and patients were included at inception on a population basis. The use of incident cases and re-evaluation of diagnosis at follow-up helped to exclude misdiagnosis. Population-based studies which use an administrative database may include both incident and prevalent cases and patient follow-up can be limited. In contrast, inception cohorts, such as ours, report true incidence of disease, avoid selection bias from referral centers in which patients with more severe disease are usually treated, and allow prospective evaluation of the disease course over time. We included patients seen at the onset of the disease excluding misdiagnosed cases; and subjects were followed up from disease onset to end of the study period. All patients were followed up during the same time period so that those who completed follow-up had comparable observation times. In practice this is difficult to achieve in most countries in Asia. Several measures were employed to ensure completeness of follow-up and the robustness of the data 3 . Many previous population-based studies were conducted before the era of disease-modifying agents. Our cohort was unselected and represented a wide spectrum of disease activity and severity across Asia; the choices of treatment therefore reflected real life settings outside the strict realms of randomised controlled trials. We believe these results may improve management of patients with CD by defining changes in phenotype of the disease over time, risk of relapse, risk of receiving corticosteroids and its efficacy, and risk of surgery. We also identified factors shown in population-based cohorts to be associated with natural history of CD.
This study also has limitations. Firstly, participating centres had heterogenous and variable health care systems therefore choice of drug and surgical therapy may have been influenced by M A N U S C R I P T
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20 access to health care. As the ACCESS cohort consisted of subjects recruited from centres in urbanized regions, we were unable to define disease outcomes in individuals from rural areas.
Secondly, lost to follow up rate was 15% and reflects the real life challenges of patient care.
Thirdly, given that this study assessed outcome at one year, longer-term follow-up of this cohort is needed in order to assess whether the earlier and more frequent immunomodulators and biological treatment observed in this study will change the natural disease course and phenotypes over time or merely postpone outcomes such as surgery. Fourthly, changes in disease extent may not be accurate especially if repeat assessment through objective measures such as imaging and endoscopy was not routinely performed for all subjects.. Lastly, some countries contributed small number of cases. We found that the majority of subjects in all 8 countries with low number of cases were clustered in one group, and clustering did not sharply divide countries into distinct groups with regard disease outcomes including surgery, disease change and drug therapy.
In conclusion, this prospective population based study showed that the early disease course for CD in Asia can be as severe as in the West. Surgical rates for CD were similar between Asia and Australia whereas surgical rates for UC remain low. These results may help to develop therapeutic strategies aimed at modifying the clinical course of IBD and provide clear and comprehensive information to the patient about disease prognosis. Continuous follow-up of our cohort will determine whether the relatively aggressive drug approach of immunomodulator therapy applied in the cohort will influence the rate of complications in the future as UC and CD are dynamic diseases that without treatment progress in extent and behavior over time. 34 (100) 12 ( Less than 6 months follow up N=74
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